The EVO ICL has a strong safety record. In the three-year FDA clinical trial covering 629 eyes, there were no cases of pupillary block or pigment dispersion, and the rate of cataract formation was 0.16%. Serious complications requiring additional surgery were rare, and the lens can be removed if problems arise. That said, like any surgical procedure, it carries real risks worth understanding before you commit.
What the FDA Trial Found
The most comprehensive safety data comes from a prospective, multicenter U.S. clinical trial that followed 629 eyes for three years after EVO ICL implantation. The safety index at three years was 1.25, meaning patients on average saw better with the lens than they did with glasses or contacts before surgery.
The most common issue was a temporary spike in eye pressure shortly after the procedure. About 20% of eyes showed elevated pressure at the one-to-six-hour checkup, caused by a gel-like substance used during surgery that hadn’t fully cleared yet. This resolved on its own. A smaller group, 2.4% of eyes, developed pressure increases from steroid eye drops used during recovery, which were managed by adjusting the medication.
Cataract formation, historically the biggest concern with implantable lenses, was exceptionally low. Only one eye (0.16%) developed a cataract that affected vision, first noticed two years after surgery. Two additional eyes (0.32%) showed tiny lens opacities that caused no symptoms. One traumatic cataract occurred in a separate eye but was linked to an injury rather than the lens itself. In all cases requiring cataract surgery, vision was fully restored afterward.
Retinal detachment occurred in three eyes (0.48%) across two patients. This is a known risk for people with high myopia regardless of whether they’ve had any vision correction procedure, since severely nearsighted eyes have thinner, more stretched retinas.
How It Compares to LASIK for Dry Eye
One of the practical advantages of the EVO ICL is that it doesn’t reshape your cornea or cut a flap in it, which means it largely avoids the chronic dry eye issues associated with laser procedures. A study comparing patients 5 to 15 years after surgery found meaningful differences between LASIK and ICL groups. Tear film hyperosmolarity, a marker of dry eye, was significantly elevated in LASIK patients compared to people who never had surgery (73% vs. 50%). The ICL group showed no such difference from the control group.
Subjective dry eye symptoms in the ICL group matched the general population. On a standardized questionnaire, 31% of ICL patients reported notable symptoms, identical to the rate in people who’d never had eye surgery. If you already deal with dry eyes or worry about developing them, the ICL’s advantage here is real and lasting.
The Reversibility Factor
Unlike LASIK, which permanently removes corneal tissue, the EVO ICL can be taken out. This is one of its most important safety features. If your prescription changes significantly, if a complication develops, or if you simply need cataract surgery decades later, the lens can be removed or exchanged.
In the FDA trial, the overall rate of secondary surgeries was low. Two eyes needed the lens repositioned and then exchanged due to changes in the front chamber of the eye. One lens was removed because the patient experienced persistent halos and glare. One was exchanged for a better-fitting size. In a separate long-term study following patients for an average of 12 years, no patients required cataract surgery after ICL removal, suggesting the eye recovers well once the lens comes out.
A large single-center U.S. study reported a 4.8% rate of postoperative adjustments, which includes lens rotations (for the astigmatism-correcting version), exchanges, and laser touch-ups. That means roughly 95 out of 100 eyes needed no follow-up procedures at all.
Long-Term Cell Loss to Watch
The cells lining the inner surface of your cornea, called endothelial cells, don’t regenerate. Any procedure inside the eye carries some risk of gradually reducing their count. The long-term data here is reassuring but worth knowing: the average loss was about 1.1% per year over a 12-year follow-up period. That’s a modest rate, but it compounds. Projected out to 20 years, cumulative loss could reach around 22%.
This is why surgeons check your endothelial cell count before approving you for the procedure and why annual monitoring is recommended for as long as the lens is in your eye. If cell counts ever drop to concerning levels, the lens can be removed before any damage to your cornea occurs.
Who Can and Can’t Get It
The FDA approved the EVO ICL for patients aged 21 to 60 (expanded from the original upper limit of 45) with myopia between -3.0 and -20.0 diopters. If you also have astigmatism, the toric version covers up to 4.0 diopters of cylinder correction. Your prescription needs to have been stable within half a diopter for at least a year before surgery.
The key anatomical requirement is an anterior chamber depth of at least 3.0 millimeters. This is the space between your cornea and your natural lens where the ICL sits. If this space is too shallow, the lens could crowd your natural lens or block fluid drainage, raising eye pressure. Your surgeon will measure this precisely during your evaluation.
You’re not a candidate if you have glaucoma with moderate to severe optic nerve damage, a history of inflammation inside the eye, diabetic retinopathy, or insulin-dependent diabetes. Conditions that affect fluid drainage in the eye, like pseudoexfoliation or pigment dispersion syndrome, also rule you out. Pregnant or nursing individuals should wait, as hormonal changes can temporarily shift your prescription.
What the Risks Actually Look Like Day to Day
The most commonly discussed side effect is halos and glare around lights at night. In the FDA trial, one patient found this bothersome enough to have the lens removed. For most people, visual disturbances like halos diminish significantly over the first few months as the brain adapts, though some degree of nighttime glare can persist.
The short-term recovery is typically fast. Most people notice dramatically improved vision within a day. The pressure spikes that affect roughly one in five patients in the first few hours are monitored at your same-day postoperative visit and almost always resolve without intervention. Steroid-related pressure increases in the weeks after surgery are caught at follow-up appointments and handled by tapering or switching your eye drops.
The serious but rare complications, including cataract formation (0.16% symptomatic), retinal detachment (0.48%), and lens repositioning or exchange (0.32%), all occurred at rates below 1%. For context, the overall complication profile compares favorably to LASIK, particularly for patients with high myopia where laser procedures carry their own elevated risks of corneal weakening and regression.